Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction?

International Journal of Cardiology

Volumn 137, Issue 3, 2009, Pages 206-215

  Bond, Mary ^a   Mealing, Stuart ^a   Anderson, Rob ^a   Dean, John ^b   Stein, Ken ^a   Taylor, Rod S ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cost benefit analysis; Defibrillation; Heart failure; Pacing; Resynchronisation

Indexed keywords

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; DEVICE; ECONOMIC EVALUATION; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; LIFESPAN; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; PROBABILITY; QRS COMPLEX; QUALITY ADJUSTED LIFE YEAR; SIMULATION; SUDDEN DEATH; SYSTOLIC DYSFUNCTION; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CARDIAC PACING, ARTIFICIAL; COST-BENEFIT ANALYSIS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC POWER SUPPLIES; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70749147370     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.05.073     Document Type: Article

References (41)

1. Bradley D.J., Bradley E.A., Baughman K.L., et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA 289 (2003) 730-740
2. Freemantle N., Tharmanathan P., Calvert M.J., Abraham W.T., Ghosh J., and Cleland J.G.F. Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction - a systematic review and meta-analysis. Eur J Heart Fail 8 (2006) 443-440
3. Abdulla J., Haarbo J., Køber L., and Torp-Pedersen C. Impact of implantable defibrillators and resynchronization therapy on outcome in patients with left ventricular dysfunction - a meta-analysis. Cardiology 106 (2006) 249-255
4. Rivero-Ayerza M., Theuns D.A.M.J., Garcia-Garcia H.M., Boersma E., Simoons M., and Jordaens L.J. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 27 (2006) 2682-2688
5. McAlister F.A., Ezekowitz J., Hooton N., et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 297 (2007) 2502-2514
6. Lam S.K., and Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 335 (2007) 925-928
7. Banz K. Eucomed CRT Steering Committee. Cardiac resynchronization therapy (CRT) in heart failure - a model to assess the economic value of this new medical technology. Value Health 8 (2005) 128-139
8. Fattore G., Landolina M., Bontempi L., et al. Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness. Ital Heart J Suppl 6 (2005) 796-803
9. Calvert M.J., Freemantle N., Yao G.Q., et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 26 (2005) 2681-2688
10. Caro J.J., Guo S., Ward A., Chalil S., Malik F., and Leyva F. Modelling the economic and cost sequences of cardiac resynchronization in the UK. Curr Med Res Opin 22 (2006) 1171-1179
11. Heevey A., Laurer M., AlSolaiman F., Czerr J., and James K. Cost-effectiveness of biventricular pacemakers in heart failure patients. Am J Cardiovasc Drugs 6 (2006) 129-137
12. Yao G., Freemantle N., Calvert M.J., Stirling B., Daubert J.-C., and Cleland J.G.F. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 28 (2007) 42-51
13. Rawlins M.D., and Culyer A.J. National Institute for Clinical Excellence and its value judgments. BMJ 329 (2004) 224-227
14. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Eng J Med 350 (2004) 2140-2150
15. Buxton M., Caine N., Chase D., et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess 10 27 (2006) 1-164 iii-iv, ix-xi
16. Braunschweig F. Devices in heart failure: building the evidence. Eur Heart J 27 (2006) 2617-2618
17. Daubert J.C., Leclerq C., and Mabo P. There is plenty of room for cardiac resynchronization therapy devices without back-up defibrillators in the electrical treatment of heart failure. J Am Coll Cardiol 46 (2005) 2204-2207
18. Daubert J.C., Leclerq C., Donal E., and Mabo P. Cardiac resynchronization therapy in heart failure: current status. Heart Fail Rev 11 (2006) 147-152
19. McAlister F.A. Device therapy in heart failure. BMJ 335 (2007) 895-896
20. Sonnenberg F.A., and Beck J.R. Markov models in medical decision making: a practical guide. Med Decis Mak 13 (1993) 322-338
21. Cowie M.R., Wood D.A., Coats A.J., et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 20 (1999) 421-428
22. M. Fox, S. Mealing, R. Anderson, et al. The effectiveness and cost-effectiveness of cardiac resynchronisation therapy (biventricular pacing) for heart failure: a systematic review and economic model. Health Technol Assess 2007;11(47).
23. Calvert M.J., Freemantle N., and Cleland J.G. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 7 (2005) 243-251
24. Kirsch J., and McGuire A. Establishing health state valuations for disease specific states: an example from heart disease. Health Econ 9 (2000) 149-158
25. McAlister F., Ezekowitz J., Wiebe N., Rowe B., Spooner C., and Crumley E. Cardiac resynchronization therapy for congestive heart failure. Agency for Healthcare Research and Quality (AHRQ) (2004). http://www.ahrq.gov/downloads/pub/evidence/pdf/resynchf/resynchf.pdf Rockville, VA, USA. http://www.ahrq.gov/downloads/pub/evidence/pdf/resynchf/resynchf.pdf (last downloaded 20th October 2006)
26. NHS National Schedule of Reference Costs (NSRC). Elective hospital admission costs (2005). http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/NHSReferenceCosts/fs/en http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/FinanceAndPlanning/NHSReferenceCosts/fs/en (last accessed 1st September 2006)
27. NHS Scotland, Indicative budget for ICDs and CRTs within NHS Scotland. Paper for November 2005 meeting of Intervention Subgroup of NHS Scotland (coronary heart Disease) http://www.chd.scot.nhs.uk/docs/Intervention_Docs/Intervention%20Sub-Group%20Agendas/Electrophysiology%20Costing%20nov%2005%20mtg.doc (last accessed 23rd May 2006).
28. British Medical Association & Royal Pharmaceutical Society of Great Britain, British National Formulary (BNF) no. 51. March 2006. London, UK.
29. National Institute for Clinical Excellence, Guide to the methods of technology appraisal (N0515). http://www.nice.org.uk/page.aspx?o=201973 (last accessed 20th October 2007).
30. Fenwick E., Claxton K., and Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10 (2001) 779-787
31. Abraham W.T., Young J.B., Leon A.R., et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 110 (2004) 2864-2868
32. Ezekowitz J.A., Armstrong P.W., and McAlister F.A. Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized controlled trials. Ann Intern Med 138 (2003) 445-452
33. Higgins S.L., Hummel J.D., Niazi I.K., et al. Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol 42 (2003) 1454-1459
34. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Eng J Med 352 (2005) 1539-1549
35. Cleland J.G.F., Daubert J.C., Erdmann E., et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the Cardiac Resynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 27 (2006) 1928-1932
36. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Eng J Med 346 (2002) 1845-1853
37. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 337 (1997) 1576-1583
38. Irvine J., Dorian P., Baker B., et al. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J 144 (2002) 282-289
39. National Institutes of Health. Resynchronization/defibrillation for advanced heart failure trial (NCT00251251). NIH: ClinicalTrials.gov (2006). http://www.clinicaltrials.gov/ct/show/NCT00251251 http://www.clinicaltrials.gov/ct/show/NCT00251251 [last accessed 23rd October 2007]
40. Moss A.J., Brown M.W., Cannom D.S., et al. Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol 10 4 Suppl (2005) 34-43
41. Coats A.J. Ethical authorship and Publishing. Int J Cardiol 131 (2009) 149-150